FH

Foghorn Therapeutics Inc.NASDAQ FHTX Stock Report

Last reporting period 30 Sep, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.529

Micro

Exchange

XNAS - Nasdaq

FHTX Stock Analysis

FH

Uncovered

Foghorn Therapeutics Inc. is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-7/100

Low score

Market cap $B

0.529

Dividend yield

Shares outstanding

41.804 B

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 161 full-time employees. The company went IPO on 2020-10-23. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The firm is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. The company is also developing FHD-609, a targeted protein degrader, and which is evaluating in a Phase I study in synovial sarcoma.

View Section: Eyestock Rating